Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Says that results from its Phase 1/2 MATINS trial of bexmarilimab have been published in Cell Reports Medicine, an open-access journal. According to the trial, bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumours. It also showed that CLEVER-1 targeting is safe and well-tolerated with no serious adverse effects, and that bexmarilimab induced macrophage activation and increased IFNy signalling in patients who achieved disease control and prolonged survival.
Current stock price: 300.00 pence, up 15% in London on Thursday
12-month change: down 17%
Copyright 2023 Alliance News Ltd. All Rights Reserved.
